SSA
KPTI icon

Schonfeld Strategic Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,333
Closed -$30K – 863
2018
Q1 		$30K Buy
+3,333
New +$665K ﹤0.01% 721

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Schonfeld Strategic Advisors's KPTI Position: Q3 2024 in Review

Schonfeld Strategic Advisors sold out of Karyopharm Therapeutics (KPTI) in Q3 2024, closing a stake of 3,840 shares — an estimated $50K sold.

Schonfeld Strategic Advisors first reported a position in KPTI in Q1 2017 and held it in 17 quarters. The position peaked at $7.12M in Q3 2018. 91 funds tracked by Wall St. Rank hold KPTI as of Q3 2024.

  • Schonfeld Strategic Advisors reported no remaining Karyopharm Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 3,840 Karyopharm Therapeutics shares in Q3 2024, an estimated $50K.
  • Schonfeld Strategic Advisors first reported a position in Karyopharm Therapeutics in Q1 2017 and held it in 17 quarters.
  • Schonfeld Strategic Advisors's Karyopharm Therapeutics position peaked at $7.12M in Q3 2018.
  • 91 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.